ACSL4 (F6T3Z) Rabbit Monoclonal Antibody#38493,Cell Signaling Technology (CST),38493
ACSL4 (F6T3Z) Rabbit Monoclonal Antibody recognizes endogenous levels of total ACSL4 protein. Species reactivity for immunofluorescence is human only.
Host
Rabbit
Reactivity
Human, Mouse, Rat
Application
Western Blotting: 1:1000 Simple WesternTM: 1:10 - 1:50 Immunoprecipitation: 1:50 Immunofluorescence (Immunocytochemistry): 1:200
Platform ID
BAB149483829
Cell Signaling Technology (CST)
Contact
Tel: 877-616-2355,978-867-2388
Fax: 877-616-2355
Email:
Specifications
Scientific Background
The long-chain fatty acyl-CoA synthetase (ACSL) family of enzymes convert free long-chain fatty acids into their active form, acyl-coenzyme A (acyl-CoA), and play dominant roles in both anabolic (fatty acid synthesis and lipogenesis) and catabolic (lipolysis and fatty acid β-oxidation) pathways (1). Acyl-CoA synthetase long-chain family member 4 (ACSL4) preferentially catalyzes the formation of arachidonoyl-coenzyme A (AA-CoA) by inserting coenzyme A (CoA) into arachidonic acid (AA) (1). ACSL4-catalyzed acyl-CoAs also participate in the regulation of steroidogenesis (2), eicosanoid biosynthesis (3), and phospholipid remodeling (4). ACSL4 is an essential enzyme for the conversion of two key ferroptosis-inducing signals, oxidized arachidonic and adrenic phosphatidylethanolamines (5,6). Genome-wide CRISPR/Cas9-based genetic screens have demonstrated that ACSL4 is an essential component for ferroptosis execution (6), and genetic or pharmacological inhibition of ACSL4 can initiate a specific anti-ferroptotic rescue pathway (5). ACSL4 expression is upregulated in ferroptosis-sensitive cancer cells compared with ferroptosis-resistant cells (7) and has been shown to predict sensitivity to ferroptosis in a panel of basal-like breast cancer cell lines (6). Moreover, high ACSL4 protein expression in hepatocellular carcinoma (HCC) clinical tissue specimens is associated with improved patient outcomes after sorafenib treatment and could serve as a predictive biomarker (8).Quan, J. et al. (2021)Eur J Pharmacol909, 174397.Cornejo Maciel, F. et al. (2005)J Mol Endocrinol34, 655-66.Kuwata, H. et al. (2014)Biochim Biophys Acta1841, 44-53.Killion, E.A. et al. (2018)Mol Metab9, 43-56.Kagan, V.E. et al. (2017)Nat Chem Biol13, 81-90.Doll, S. et al. (2017)Nat Chem Biol13, 91-98.Yuan, H. et al. (2016)Biochem Biophys Res Commun478, 1338-43.Feng, J. et al. (2021)Acta Pharmacol Sin42, 160-170.Alternate NamesACS4; ACSL4; acyl-CoA synthetase 4; acyl-CoA synthetase long chain family member 4; acyl-CoA synthetase long-chain family member 4; Arachidonate--CoA ligase; FACL4; fatty-acid-Coenzyme A ligase, long-chain 4; LACS 4; LACS4; lignoceroyl-CoA synthase; Long-chain acyl-CoA synthetase 4; long-chain fatty-acid-Coenzyme A ligase 4; Long-chain-fatty-acid--CoA ligase 4; MRX63; MRX68
Synonyms
ACS4; ACSL4; acyl-CoA synthetase 4; acyl-CoA synthetase long chain family member 4; acyl-CoA synthetase long-chain family member 4; Arachidonate--CoA ligase; FACL4; fatty-acid-Coenzyme A ligase, long-chain 4; LACS 4; LACS4; lignoceroyl-CoA synthase; Long-chain acyl-CoA synthetase 4; long-chain fatty-acid-Coenzyme A ligase 4; Long-chain-fatty-acid--CoA ligase 4; MRX63; MRX68
Category Paths
- Products>Trial Size Antibodies
Please provide the required information below so that we can quickly source your products.
